1. Scrip
  2. >>Business
  3. >>Strategy

Blueprint RETreats As It Sells US Gavreto Rights To Rigel

Drug Will Be Pulled In Most Markets

 
• By Alaric DeArment

After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.

• Source: Shutterstock

Rigel Pharmaceuticals, Inc. is beefing up its product portfolio with one of the only two RET inhibitors on the market, Blueprint Medicines Corporation’s Gavreto (pralsetinib), with its purchase of US rights from Blueprint for potentially more than $100m. Blueprint, meanwhile, is offloading a drug that had proven commercially disappointing, and in addition to selling US rights it plans to cease marketing of Gavreto outside the US and Greater China.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.